Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
28.49
42.6522
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Accounts Receivables
Chengdu Easton Biopharmaceuticals Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
|
Accounts Receivables
¥120.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accounts Receivables
¥3.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Accounts Receivables
¥809.6m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
14%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accounts Receivables
¥6.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accounts Receivables
¥10.1B
|
CAGR 3-Years
21%
|
CAGR 5-Years
36%
|
CAGR 10-Years
28%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Accounts Receivables
¥98.4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Chengdu Easton Biopharmaceuticals Co Ltd
Glance View
Chengdu Easton Bio Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of chemical raw materials and chemical drug preparations. The company is headquartered in Chengdu, Sichuan and currently employs 1,188 full-time employees. The company went IPO on 2020-09-02. The firm's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The firm operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.
See Also
What is Chengdu Easton Biopharmaceuticals Co Ltd's Accounts Receivables?
Accounts Receivables
120.2m
CNY
Based on the financial report for Dec 31, 2023, Chengdu Easton Biopharmaceuticals Co Ltd's Accounts Receivables amounts to 120.2m CNY.
What is Chengdu Easton Biopharmaceuticals Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
6%
Over the last year, the Accounts Receivables growth was -12%.
You don't have any saved screeners yet
